PFE : Analysis & Opinions

  • Showing 101-167 of 167 items
  • <<
  • 1
  • 2
  1. 7 Dividend Stocks With Big Payouts

    May 4, 2011
    Dividend increases are being seen across the board. Find out which stocks are offering the biggest payouts.
  2. Teva And Cephalon Solve Each Other's Problems

    May 4, 2011
    Teva's acquisition of Cephalon is a logical deal that solves problems for each company.
  3. Despite The Noise, Abbott Still A Value

    April 25, 2011
    Abbott has made some curious moves of late, but the value is still there.
  4. Spinoffs Becoming The Rage

    April 6, 2011
    Spinoffs from all sectors and industries seem to be increasing in number, as companies look to get stock prices moving and ...
  5. Glaxo And Human Genome Find Rare FDA Success

    March 10, 2011
    With an increasingly scarce FDA approval in hand, HGSI and GSK look to build a blockbuster drug.
  6. PBMs: Making The Most Of Generics

    February 3, 2011
    PBMs stand to benefit from the generic introduction of blockbuster drugs. Has the market fully discounted the opportunity? ...
  7. A Look At The Drug Makers Of 2010

    December 30, 2010
    Drug makers faced an uphill fight in 2010 and next year is looking to be just as tough.
  8. 5 Low-Beta Stocks To Know In 2011

    December 29, 2010
    Check out five low-beta stocks that can help you to diversify your portfolio.
  9. InterMune - The Black Knight Of Biotech?

    December 21, 2010
    Possible European approval could save the day for this risky biotech.
  10. Pfizer Ready To Create Value

    December 15, 2010
    Overall, Pfizer is a company with a cheap stock price, earnings power and numerous options to reward shareholders.
  11. The Curious And Complicated Case Of MannKind

    December 15, 2010
    MannKind is a classic high-risk high-reward biotech story.
  12. 5 Low-Beta DJIA Stocks To Know

    December 14, 2010
    Check out five low-beta stocks that can help you to diversify your portfolio.
  13. Jacobs Still Looking To Build That Ladder

    November 18, 2010
    Jacobs closed out a tough year, but a quick rebound in large-scale construction seems improbable.
  14. Expected Increase In Research And Development

    November 8, 2010
    Research & Development (R&D) is the key to success in the pharmaceutical industry, but just how much of an impact ...
  15. Allergan Winning Wall Street's Beauty Pageant

    November 3, 2010
    Allergan's earnings aren't special, but the stock is basking in Wall Street's love. Is it simply a case of lipstick on a ...
  16. 7 Reasons To Pick ETFs Over Stocks

    November 1, 2010
    As a cost-effective way to achieve a broadly diversified portfolio, including hard-to-own (but worthwhile) assets, ETFs are ...
  17. Should Investors Take A Chance On Savient?

    October 26, 2010
    Savient's inability to sell itself puts almost everything about the company's value in flux.
  18. BIG Dividends, BIG Returns

    October 22, 2010
    High dividend paying stocks are present in many industries. But do you know how to analyze a balance sheet to ensure that ...
  19. Abbott Labs Showing Meaningful Growth

    October 21, 2010
    Abbott might just be the best healthcare stock today.
  20. Invest In The Lip Balm Portfolio

    October 5, 2010
    Themed portfolios can often exceed established ones in performance - and the lip balm portfolio is just one example.
  21. 5 Dow 30 Stocks With Huge Dividends

    October 1, 2010
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  22. FDA To Obesity Drugs: Drop Dead

    September 20, 2010
    An FDA panel knocks down yet another would-be obesity drug.
  23. Pfizer's Decision Leaves Celldex Reeling

    September 7, 2010
    We'll look at what Pfizer withdraw of support for Celldex's cancer vaccine means for the biotech's stock.
  24. Top-Heavy Pharmaceuticals

    August 27, 2010
    Investors should keep an eye on how much drug companies rely on its top sellers.
  25. Big Pharma's Big Problem

    August 16, 2010
    Big Pharma's best patents are expiring, but it may be able to reinvent itself through acquisitions.
  26. 3 Hearty Healthcare Investments

    August 6, 2010
    Should the broad market find its legs, look for these issues to outperform.
  27. 5 Stocks With Solid Cash Flow

    August 3, 2010
    While a company's reported earnings may not tell the whole story, cash flow usually does.
  28. Investing Like A Contrarian

    July 21, 2010
    When everyone is selling, it may be the time to buy, so says contrarian investing.
  29. Novartis On The Right Track

    July 19, 2010
    With recent sales increases and a solid pipeline, Novartis deserves a spot on the watchlist of anybody looking at Big Pharma. ...
  30. Cancer Vaccines Continue To Show Promise

    July 7, 2010
    Dendreon has put cancer vaccines back in the spotlight, but can they live up to their hype?
  31. Pharmaceuticals With Big Returns

    June 22, 2010
    These intriguing Pharmaceuticals currently have big returns.
  32. Stocks That Protect Against Deflation

    June 21, 2010
    Although recent data suggests prices may be falling, inflation may still take over in the long term due to the excess liquidity ...
  33. The Future of Stem Cells

    June 15, 2010
    Stem cells get a lot of attention, but maybe not in the one area where they could prove most effective.
  34. Are These Dividends For Real?

    May 21, 2010
    Though they have their downfalls, dividends are a reliable source of capital.
  35. Fairholme's Financial Bet

    May 21, 2010
    As of the end of the first quarter of 2010, Fairholme was making a big bet. The move was not on one single company, but on ...
  36. Relief With Bristol-Myers Squibb

    May 6, 2010
    BMY's strong reaction after first-quarter earnings seems more like relief, as the company still has many challenges to surmount. ...
  37. Pfizer Delivers A Healthy Quarter

    May 6, 2010
    Despite forecasting adjusted earnings of over $2 a share for 2010, Pfizer shares remain at $17.
  38. Small Med-Tech Names You Should Know

    April 15, 2010
    These three med-tech names aren't well-known by most investors, but they should be.
  39. 3 Healthy Healthcare Stocks

    April 6, 2010
    Strong dividends offer additional safety to investors concerned about the bull market's sustainability.
  40. Pharmaceutical Profits That Aren't For The Dogs

    March 15, 2010
    Merck and Sanofi-Aventis recently combined their animal health businesses, lending further evidence to the notion that this ...
  41. 5 Reasons To Love Greenlight Capital Re

    March 11, 2010
    David Einhorn, noted investor, is Chairman and largest shareholder of this Cayman Island reinsurance company.
  42. 3 Biotech Stocks On The Move

    March 10, 2010
    All three of these biotech companies are swinging for the fences and this approach has been reflected in their stock prices. ...
  43. 4 U.S. Companies With High Currency Exposure

    February 24, 2010
    The U.S. dollar has been strengthening against the euro which is a bad sign for the U.S. exporters as the goods become more ...
  44. Let's Play The Dow Dividend Game

    January 29, 2010
    These three companies are strong alternatives to Dow dividend payers.
  45. Stocks That LEAP Out At You

    January 19, 2010
    Certain opportunities exist that can make the use of LEAPS a very intriguing bet.
  46. Count The Cash At Dell

    November 24, 2009
    Cash matters, and Dell produces tons of it. Successful execution of its strategic initiatives should lead to more cash generation ...
  47. Why Today's Market Dictates Pessimism

    November 18, 2009
    Investing as if the markets can only go up is a recipe for disaster, while embracing pessimism will keep you in the game. ...
  48. The 5 Most Important Drugs In America

    July 28, 2009
    A look at the top-selling drugs finds that a few that make more of a difference to the company's bottom line than others. ...
  49. High Yield Bets For The Conservative Investor

    July 24, 2009
    High dividends and long-term dependability make it worth getting involved with these companies.
  50. Is Pfizer What The Doctor Ordered Or Bad Medicine?

    April 30, 2009
    Explore Pfizer, its earnings and its recent acquisition deal.
  51. Medical Devices: Cure For Ailing Portfolios?

    February 27, 2009
    Find out how these medical device makers may resuscitate your ailing portfolio.
  52. Invest In The Original S&P 500

    February 18, 2009
    An amazing number of the original companies in the S&P 500 index are still trading. I'll pick out some interesting choices ...
  53. Bristol-Myers Pays Healthy Dividends

    February 12, 2009
    Bristol-Myers is among five companies with a great forward annual dividend yield.
  54. Aging Population Feeds Global Healthcare Demand

    October 30, 2008
    Investing in foreign-based healthcare providers is as important as investing in healthcare providers with a global reach. ...
  55. Ride The Ups And Downs Of Drug Approval

    October 16, 2008
    The FDA's complex drug approval process provides plenty of volatility for short-term traders to feast upon.
  56. 10 Blue Chips On The Outs

    October 8, 2008
    The market has taken down stocks of all caliber, and these formerly sturdy blue chip stocks are due another look as we wait ...
  57. Making Sense Of Cash And Shorts

    September 29, 2008
    We examine a group of mutual funds that have large cash positions either from short selling or from asset allocation.
  58. Actively Managed ETFs

    August 5, 2008
    Actively managed ETFs need more time to run before investors can truly determine if passive management is superior.
  59. Merck Needs A New Megaphone

    July 24, 2008
    Learn how Merck's refusal to sell its story to Wall Street is hurting the stock and the few investors who are still hanging ...
  60. Monsanto's Double-Bottom Doubles The Fun

    April 8, 2008
    Sometimes a technical trend is so prominent it's impossible to ignore. Monsanto's double-bottom chart could point to a new ...
  61. Duke Energy Is High Yield Royalty

    March 4, 2008
    Duke Energy's very healthy dividend yield makes it a solid investment as a fixed-income proxy, especially during a flight ...
  62. Pfizer's Exubera Pflops (PFE)

    October 25, 2007
    Pfizer took a $2.8 billion hit when it cancelled Exubera from its product line - is the worst now over, or is there more ...
  63. Johnson & Johnson Blows Away Q1 (JNJ)

    April 20, 2007
    J&J beat its Q1 consensus number with ease, so where is the stock is headed from here?
  64. Generic Manufacturers Go After Big Pharma

    March 14, 2007
    Generic drug manufacturers continue pose a potent threat to the established "big pharma" companies.
  65. You Gotta Know When To Bail

    February 22, 2007
    When your stock's prospects take a turn for the worse, bailing out can be the best possible option.
  66. Bristol-Myers Hurt By Plavix, Saved By Demographics (BMY)

    November 16, 2006
    Despite BMY's recent struggles with its Plavix sales, favorable demographics make the stock a good investment to consider. ...
  67. Pfizer, Pass the Rolaids

    June 12, 2006
    $15 billion for its consumer products unit won’t cure Pfizer’s ailing stock.
  68. A Look at Economic Moats - Part 2

    November 23, 2005
    In this piece we'll explore different types of economic moats.
  • Showing 101-167 of 167 items
  • <<
  • 1
  • 2
Trading Center